Literature DB >> 18936348

The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.

Katherine C Yung1, Jay F Piccirillo.   

Abstract

OBJECTIVE: To investigate the incidence and prognostic impact of comorbidities diagnosed after the onset of head and neck cancer.
DESIGN: Retrospective review of medical records. PATIENTS: One hundred eighty-three patients diagnosed as having head and neck cancer at Washington University School of Medicine from January 1, 1997, through December 31, 1998. MAIN OUTCOME MEASURES: We reviewed medical records for demographic, tumor, treatment, and comorbidity data. Comorbid ailments at diagnosis and last follow-up or death were coded using the Adult Comorbidity Evaluation-27.
RESULTS: Of the 183 patients, 53 (29.0%) were found to have a baseline comorbidity score of none; 58 (32.0%) of mild; 53 (29.0%) of moderate; and 19 (10.4%) of severe. At last follow-up or death, scores were none for 30 patients (16.4%), mild for 52 (28.4%), moderate for 43 (23.5%), and severe for 58 (31.7%). Comorbidity scores at baseline (P = .002) and last follow-up (P = .001) were associated with 5-year survival. The prognostic impact of comorbidity scores at baseline and last follow-up were analyzed using Cox proportional hazards analysis. Individual comorbid ailments after diagnosis included myocardial infarction, coronary artery disease/angina, solid tumor, psychiatric disease, chronic obstructive pulmonary disease, hypertension, and alcohol abuse.
CONCLUSIONS: These findings are consistent with previous research demonstrating that comorbidity at diagnosis is strongly correlated with prognosis. This study also showed that the burden of comorbidity changes after diagnosis. There appeared to be a prognostic gradient based on comorbidity severity at baseline and outcome despite adjusting for age, sex, and cancer stage. Additional studies with larger numbers of patients and longer follow-up should be performed to investigate the importance of comorbidities that arise after diagnosis and may be a result of treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18936348     DOI: 10.1001/archotol.134.10.1045

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  16 in total

1.  Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.

Authors:  Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek
Journal:  Head Neck       Date:  2016-07-19       Impact factor: 3.147

Review 2.  Management of head and neck cancer in elderly patients.

Authors:  Yassine Lalami; Gilberto de Castro; Chantal Bernard-Marty; Ahmad Awada
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

4.  Comparison of Scoring Methods for ACE-27: Simpler Is Better.

Authors:  Dorina Kallogjeri; Jay F Piccirillo; Edward L Spitznagel; Ewout W Steyerberg
Journal:  J Geriatr Oncol       Date:  2012-07-01       Impact factor: 3.599

5.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.

Authors:  Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

6.  Surgery for pulmonary malignancies in patients with a previous history of head and neck squamous cell carcinoma.

Authors:  Ryu Kanzaki; Masayoshi Inoue; Masato Minami; Yasushi Shintani; Tomoyuki Nakagiri; Soichiro Funaki; Mikihiko Kogo; Yoshiaki Yura; Hidenori Inohara; Noriyoshi Sawabata; Meinoshin Okumura
Journal:  Surg Today       Date:  2013-04-16       Impact factor: 2.549

7.  Prognostic impact of pretherapeutic laboratory values in head and neck cancer patients.

Authors:  Franziska Peter; Claus Wittekindt; Mira Finkensieper; Michael Kiehntopf; Orlando Guntinas-Lichius
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-25       Impact factor: 4.553

8.  Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population.

Authors:  Ashish A Ankola; Richard V Smith; Robert D Burk; Michael B Prystowsky; Catherine Sarta; Nicolas F Schlecht
Journal:  Oral Oncol       Date:  2013-07-25       Impact factor: 5.337

9.  Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma.

Authors:  S Andrew Skillington; Dorina Kallogjeri; James S Lewis; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

10.  Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study.

Authors:  F Desplenter; C Bond; M Watson; C Burton; P Murchie; A J Lee; K Lefevre; S Simoens; G Laekeman
Journal:  Br J Cancer       Date:  2012-10-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.